- Home
- SAP vs ABBV Comparison
SAP vs ABBV Comparison
Compare SAP & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAP
- ABBV
- Stock Information
- Founded
- SAP 1972
- ABBV 2012
- Country
- SAP Germany
- ABBV United States
- Employees
- SAP N/A
- ABBV N/A
- Industry
- SAP Computer Software: Prepackaged Software
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- SAP Technology
- ABBV Health Care
- Exchange
- SAP Nasdaq
- ABBV Nasdaq
- Market Cap
- SAP 337.0B
- ABBV 370.7B
- IPO Year
- SAP 1998
- ABBV N/A
- Fundamental
- Price
- SAP $270.26
- ABBV $206.25
- Analyst Decision
- SAP Buy
- ABBV Strong Buy
- Analyst Count
- SAP 7
- ABBV 21
- Target Price
- SAP $238.00
- ABBV $212.70
- AVG Volume (30 Days)
- SAP 1.4M
- ABBV 7.0M
- Earning Date
- SAP 04-22-2025
- ABBV 04-25-2025
- Dividend Yield
- SAP 0.96%
- ABBV 3.18%
- EPS Growth
- SAP N/A
- ABBV N/A
- EPS
- SAP 2.74
- ABBV 2.39
- Revenue
- SAP $35,382,544,788.00
- ABBV $56,334,000,000.00
- Revenue This Year
- SAP $13.46
- ABBV $7.77
- Revenue Next Year
- SAP $12.32
- ABBV $8.14
- P/E Ratio
- SAP $98.32
- ABBV $86.31
- Revenue Growth
- SAP 9.51
- ABBV 3.71
- 52 Week Low
- SAP $175.08
- ABBV $153.58
- 52 Week High
- SAP $293.70
- ABBV $218.66
- Technical
- Relative Strength Index (RSI)
- SAP 47.98
- ABBV 50.87
- Support Level
- SAP $261.89
- ABBV $196.49
- Resistance Level
- SAP $280.44
- ABBV $215.50
- Average True Range (ATR)
- SAP 4.57
- ABBV 4.75
- MACD
- SAP 0.04
- ABBV -1.43
- Stochastic Oscillator
- SAP 60.89
- ABBV 51.34
About SAP SAP SE ADS
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small- to medium-size enterprises.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).